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Radiotherapy is a well-established treatment for 
a wide range of pathologies, including cancer of 
the prostate [1]. Radiotherapy consists of the de-
livery of ionising radiation to a target in order to 
treat a disease, avoiding the adjacent healthy tis-
sues. However, healthy tissues will inadvertently 
still be exposed, resulting in unwanted toxicities 
(i.e. side-effects) which are a major limitation of 
radiotherapy [2]. Even though these toxicities are 
temporary, they may result in a diminished quality 
of life for the patient, and increase the risk of devel-
oping late toxicities which are often permanent [3]. 
Prostate cancer (PCa) is the most common ma-
lignancy in men in Malta, accounting for approxi-
mately 20% of all new male cancer diagnoses [4]. 
Radiotherapy is a frequently utilised treatment for 
AbstrAct
background: There is conflicting literature regarding the effect of patient size on radiotherapy toxicities. This study aimed 
to determine whether there is any association between patient thickness and severity and incidence of acute GI toxicities of 
prostate cancer patients receiving VMaT radiotherapy. The impact of confounding factors was also examined: rectal dose, age 
and lymph node irradiation.
Materials and methods: This study used a non-experimental, retrospective, descriptive and cross-sectional design. all 
patients who complied with the inclusion criteria (n = 96) were included. GI toxicity scores (baseline and last week of radio-
therapy), rectal dose, lymph nodes irradiation and patient age at diagnosis were collected from the treatment file. patient 
separations were measured from the cT-simulator images. statistical tests were performed to analyse the influence of these 
factors on acute GI toxicities.
results: patient thickness was shown to have no statistically significant effect on the incidence (p = 0.947 for antero-posterior 
and p = 0.839 for lateral thicknesses), and severity (p = 0.986 and 0.905, respectively) of acute GI toxicities. severity of GI tox-
icities increased following radiotherapy: the expanded prostate cancer Index composite (epIc) score increased by 2.64 from 
baseline (p < 0.001). The confounding factors had no statistically significant effect on toxicities (p > 0.05).
conclusion: as expected, most patients experienced an increase in GI toxicity following radiotherapy. No relationship was 
established between patient thickness and the severity or incidence of acute GI toxicities, adding to the existing body of 
knowledge. Therefore, all patients should receive adequate follow up, irrespective of size. side-effect recording tools should 
be implemented systematically for continuous assessment of this relationship. 
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PCa, which commonly causes toxicities, with as 
many as 90% of patients developing gastrointestinal 
(GI) toxicities [5]. 
The rationale for a relationship between patient 
thickness and acute GI toxicities is as follows: an in-
crease in the patient thickness will require a higher 
radiation exposure in order to administer the pre-
scribed dose to the target which is deeper in the 
body [6]. Therefore, the adjacent normal tissues 
may receive a greater radiation dose, increasing 
toxicities. Yet, optimisation of the treatment may 
allow for administration of the dose to the target 
while avoiding the rectum. 
Although there is published literature correlating 
patient size with the radiotherapy toxicities inter-
nationally [7–13], there is a lack of knowledge with 
regards to acute GI toxicities following PCa radio-
therapy specifically. 
Furthermore, the research findings of such arti-
cles were conflicting [7, 9, 12, 13]. The majority of 
studies indicated that a larger patient size tended 
to reduce the incidence and severity of acute GI 
toxicities, and was attributed to a greater distance 
between the rectum and target due to adipose tis-
sue [7, 8, 10, 11]. Conversely, two articles reported 
that larger patient sizes lead to more GI toxicities 
[12, 14]. Moreover, three other articles indicated 
that there was no significant association between 
patient size and toxicities. This lack of associa-
tion was attributed to the use of highly accurate 
radiotherapy techniques, such as volume modu-
lated arc therapy (VMAT) and image verification, 
which would improve treatment accuracy, thereby 
limiting the exposure of the adjacent organs at risk 
(OARs) [9, 13, 15]. 
The literature presents various methods to es-
tablish the relationship between patient size and 
toxicities, leading to differences in findings and 
hindering comparison of results. A limited number 
of studies made use of thickness (also referred to as 
“separation” in some publications) to measure pa-
tient size [16], while other studies used BMI or vis-
ceral fat [7, 8, 17]. Different toxicity grading tools 
were also used to measure the toxicities across the 
different articles [13, 18]. 
This study used patient thickness as the measure-
ment of patient size, where a more significant thick-
ness reflects a larger patient size. Antero-posterior 
(AP) thickness refers to the distance between the 
front and the back aspects of the patient’s body, 
while the lateral thickness corresponds to the dis-
tance between the left and right sides of the patient 
[19]. Moreover, thickness is particularly important 
in radiotherapy since it directly affects dose distri-
bution [6]. 
In addition, several studies focused on the im-
pact of patient size on other aspects of radiotherapy, 
namely patient setup accuracy [16, 20, 21] and radi-
ation dosimetry [22–24], which may have an effect 
on radiation toxicities. Thereby, the relationship 
between patient size and toxicities is multifaceted. 
This study aimed to determine whether there is 
an association between the thickness of patients 
receiving VMAT radiotherapy for PCa and the 
severity and incidence of acute GI radiation toxici-
ties. The influence of pelvic lymph node (LN) ir-
radiation, patient age and rectal dosimetry on the 
incidence and severity of acute GI toxicities was 
also evaluated. This assessment of confounding 
factors was not considered in previously published 
studies.
This study focused on PCa cases treated with 
VMAT, for standardisation. The scope was also lim-
ited to the effect that patient thickness has on acute 
GI toxicities to ensure that the aim is achievable; 




The target population in this study included all 
patients who previously underwent VMAT to the 
prostate in a Maltese radiotherapy centre. The focus 
on PCa radiotherapy cases specifically ensured that 
the population was homogenous, removing poten-
tial confounding factors, such as different target 
sizes and dose prescriptions.
Table 1 specifies the inclusion and exclusion 
criteria used for selecting the accessible popula-
tion. Patients who did not fulfil these criteria were 
not included in this study. All PCa patients treated 
with VMAT at a Maltese radiotherapy centre who 
completed treatment prior to data collection were 
included in the study (exhaustive sampling). Fur-
thermore, all included patients were treated with 
image-guided radiotherapy using cone-beam com-
puted tomography. This allowed the sample to be-
come more representative of the target population, 
leading to more accurate generalisations. 
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Patients who had previously undergone a trans-
urethral resection of the prostate were still includ-
ed, since no dosimetric alterations are performed in 
such cases [25]. The inclusion of only patients with 
seminal vesicle irradiation in addition to the pros-
tate allowed for similar treatment volumes between 
patients. At a Maltese radiotherapy centre where 
this study took place, all radical prostate cancer 
patients receive the same dose prescription, which 
is: 60 Gy in 20 fractions over 4 weeks. Therefore, 
all included patients received the same total doses.
Data collection tools
The data was collected retrospectively by two in-
termediaries, who were experienced radiographers 
working at a Maltese radiotherapy centre. This was 
done to ensure the anonymity of patients.
The Expanded Prostate Cancer Index (EPIC) 
tool was used to collect patient data on GI tox-
icity incidence and severity. This tool allows for 
an assessment of OAR function and the degree 
of inconvenience for the patient from any toxici-
ties being experienced [26]. The EPIC tool was an 
established and validated instrument tested with 
a large randomly-selected cohort of patients, whose 
characteristics and demographics were internation-
ally representative [27]. 
At a Maltese radiotherapy centre, EPIC is per-
formed several times through radiotherapy treat-
ments. For this study the EPIC scores before starting 
radiotherapy (baseline) and during the last week 
of radiotherapy were collected (follow-up). This al-
lowed for an assessment of the contribution of ra-
diotherapy to the toxicity score following treatment. 
A data record sheet was used to collect the fol-
lowing data from each patient: Patient thickness 
(AP and lateral), EPIC score (baseline and fol-
low-up), rectal dose (D80%), LN irradiation and 
age. The validity and reliability of the data record 
sheet were tested, and it was found to be both valid 
and reliable. Validity was tested using the Content 
Validity Index for Items from the two experienced 
radiographers. The Item Content Validity Index (I-
CVI) was 1.00, demonstrating a suitable level of 
validity for the data record sheet. Moreover, reli-
ability was established by having the two interme-
diaries separately collect the data from the same 
five patients who had satisfied the inclusion and 
exclusion criteria and document it on separate data 
record sheets accordingly. The intraclass correlation 
coefficient (ICC) was then calculated to be 1.00, 
indicating excellent reliability.
In the context of this study, “incidence” of acute 
GI toxicities occured when the EPIC total score was 
greater in the last week of radiotherapy when com-
pared with the baseline. In addition, “severity” was 
the difference in EPIC total scores between the last 
week of treatment and baseline, with larger changes 
in scores being indicative of greater severity.
The EPIC scores, patient age at diagnosis, pelvic 
LN irradiation status and rectum dose-volume pa-
rameters were obtained through the patients’ medi-
cal files. The baseline EPIC scores were selected as 
at a date before starting PCa radiotherapy, whereas 
the follow-up EPIC scores were required to have 
been completed during the last week of radiothera-
py or the week following completion. 
The patient AP and lateral thicknesses were mea-
sured through the Computed Tomography-Simula-
tor (CT-Sim) images. Both AP and lateral thickness 
were measured at the level of the prostate base, 
since this is close to the centre of the radiation 
beams where the thickness will influence dose dis-
tribution the most [1]. To ensure reproducible mea-
surements clear instructions for the measurement 
of the thickness were provided to the intermediar-
table 1. selection criteria
Inclusion criteria
The patient is undergoing radiotherapy for pca
The patient has not been diagnosed with metastasis
The patient has received VMaT radiotherapy with radical intent
The pTV includes prostate and seminal vesicles (with or without lymph nodes)
The epIc forms (baseline and last week of radiotherapy) were available
The patient has received standard hormone therapy for pca
exclusion criteria   
The patient has received surgery to the prostate (e.g. radical prostatectomy)
The patient has a hip prosthesis implanted
The pTV does not include the seminal vesicles
pca — prostate cancer; VMaT — volume modulated arc therapy; pTV — planning target volume; epIc — expanded prostate cancer Index composite
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ies: the AP thickness was measured at the patient’s 
midline, while the lateral thickness was measured 
at the antero-posterior midpoint of the prostate 
gland, both measurements were performed at the 
base of the prostate gland. The same procedure was 
repeated for all patients. When multiple CT-Sim 
scans were available, the scan which was used for 
treatment planning was utilised. Rectal dose-vol-
ume parameters were obtained through the printed 
treatment plan. The parameter recorded was the 
dose to 80% of the rectum volume.
statistical analysis
IBM SPSS version 26 was used to analyse the 
data. Several non-parametric statistical tests were 
used for data analysis, summarised in Table 2. Sig-
nificance was taken when the p-value was lower 
than the 0.05 level of significance [28]. 
ethical considerations
Prior to the study, ethical clearance was obtained 
from the University Research and Ethics Commit-
tee at the University of Malta. Confidentiality was 
ensured since the identity of patients was not dis-
closed in the research data. Each patient was as-
signed a code by the intermediaries, which was 
known to them only.
results
A total of 120 PCa patients were treated since the 
introduction of VMAT to treat this pathology, with 
the EPIC forms also being available. An exhaustive 
sampling technique was used, and 96 patients were 
included, following the selection criteria (Tab. 1). 
The majority of patients were within the 71 to 75 
age-group (38.5%), which was expected since the 
mean age at diagnosis of PCa is 72 years [29]. The 
mean AP thickness was 22.87 centimetres while 
mean lateral thickness was 36.60 centimetres, with 
a standard deviation of 2.64 and 2.45, respectively. 
The mean dose to 80% of the rectum was 42.26Gy 
when an incidence of toxicities was reported and 
44.04Gy without incidence. A total of 42 patients 
reported an incidence of GI toxicities, while 54 
patients reported no increase, meaning the ratio of 
7:9. The small number of patients with LN irradia-
tion (6.3%) may limit the generalisation of results 
regarding LN, since such a small sample may not 
be representative (Tab. 3).
table 2. statistical tests used for data analysis
Statistical test Use
shapiro-Wilk test assessment of normality of data distribution 
spearman’s rank correlation coefficient
correlation between patient thickness and GI toxicity severity
correlation between rectal dose-volume parameter and severity of GI toxicities
Kruskal-Wallis test
comparison of GI toxicity severity between patients with and without nodal irradiation
comparison of GI toxicity severity between age-groups
comparison of thickness between patients who have and have not develop GI toxicities
comparison of rectal dose between patients who have and have not develop GI toxicities
chi-square test
comparison of incidence between patients with and without nodal irradiation
comparison of incidence between age-groups





65 years or less
66–70 years
71–75 years
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Most patients showed few GI toxicities through-
out the treatment period, yet, a significant increase 
(p ≤ 0.001) was observed between the baseline 
(mean EPIC score = 0.36) and after radiotherapy 
(mean EPIC score = 3.00). The relationship be-
tween the incidence and the severity of acute GI 
toxicities with thickness, rectal dose, LN irradiation 
and patient age are explored below.
relationship between thickness  
and GI toxicities
The Spearman correlation coefficients relating 
toxicity severity to AP and lateral thickness were 
both close to zero (Rs = 0.002 for AP thickness and 
Rs = 0.012 for lateral thickness), indicating a very 
weak relationship. Moreover, the p-values for AP 
and lateral thickness (0.986 and 0.905, respectively) 
show that the correlation was not statistically sig-
nificant (Fig. 1).
There was a non-significant difference (p = 0.947) 
between the AP thickness of patients who showed 
an incidence of GI toxicities (AP thickness = 23.0 
cm) in comparison with those who did not de-
velop GI toxicities (AP thickness = 22.8 cm). In 
addition, the mean lateral thickness also marginally 
differed between incidence groups, with a mean 
lateral thickness of 36.73 cm for the group with an 
incidence of toxicities and of 36.50 cm for the group 
without an incidence of toxicities.
correlation between rectal dose  
and GI toxicities
The Spearman correlation coefficient showed 
a non-significant (p = 0.535) and very weak cor-
relation between rectal dose and toxicity severity 
(Rs = –0.064). Moreover, upon analysis, it was shown 
that there was no significant difference (p = 0.404) 
in the mean dose to 80% of the rectum between the 
patient cohort with (mean D80% = 42.26 Gy) and 
without (mean D80% = 44.04 Gy) incidence of GI 
toxicities.
relationship between LN irradiation  
and GI toxicities
The Kruskal-Wallis test indicated that the mean 
severity of toxicities for patients who did not receive 
LN irradiation was only marginally higher than the 
mean severity with LN irradiation (p = 0.880). The 
Chi-Square test showed that the incidence of GI 
toxicities was similar between patients with pel-
vic LN irradiation and those without (p = 0.595). 
Thereby, no significant association was found be-
tween LN irradiation and GI toxicities. The lack of 
statistical significance may be due to the small size 
of the group with LN irradiation (n = 6).
relationship between patient age  
and GI toxicities
The mean severity of acute GI toxicities was 
the highest for the 71 to 75 year age-group (4.43) 
and the lowest for the age group of 76 years or 
more (1.00). Most patients (n = 37) were from this 
age-group. However, the difference was not statisti-
cally significant (p = 0.238).
The incidence of GI toxicities was the highest 
for the 71 to 75 age-group (45.2%), followed by the 
age group of 65 years or less(26.2%). However, the 
Chi-Square test proved that the difference in inci-
dence of GI toxicities was not significant between 
the age groups (p = 0.265).
Figure 1. scatter graph correlating severity with antero-posterior (ap) and lateral thicknesses 
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Discussion
The predominant finding from this research 
study was that neither AP nor lateral patient thick-
ness showed a statistically significant relationship 
with acute GI toxicities. As such, this study adds 
to the existing body of knowledge, further clarify-
ing the complex relationship between patient size 
and toxicities discussed in previously published lit-
erature [7–15]. Based on these findings, all patients 
undergoing PCa radiotherapy may receive similar 
radiotherapy treatments, without any dosimetric 
alterations, and similar follow-up care, irrespective 
of patient size.
The possible cause for this is the use of the 
VMAT technique which allows to administer more 
conformal dose to the targets reducing the dose 
to sensitive OARs such as the rectum. In addition, 
image-guided radiotherapy is used at a Maltese ra-
diotherapy centre, allowing higher accuracy in the 
dose administration, with a possible reduction in 
treatment margins, thereby maintaining a low dose 
to the OARs [30, 31] and limiting GI toxicities, ir-
respective of patient size. 
Patients at the end of treatment showed more GI 
toxicities. Therefore, patient care should be empha-
sised in this phase of treatment. A toxicity grading 
tool (such as the EPIC tools) could be implemented 
for all patients and treatment sites. This would al-
low for the incidence and severity of toxicities to be 
detected and treated accordingly. Moreover, future 
retrospective analysis of the data could thus be fa-
cilitated.
Furthermore, the confounding factors studied 
did not seem to have a statistically significant effect 
on toxicities. With regards to the rectal dosimetry, 
the parameter for all patients in the study was with-
in the recommended tolerance. This would limit 
the severity of GI toxicities, in line with previous 
literature [32, 33]. Moreover, only one dose-volume 
parameter was collected for the rectum (dose to 
80% of the rectal volume). As such, further studies 
are suggested with more dose-volume parameters 
for a better understanding of the confounding effect 
of dose on GI toxicities.
Although the inclusion of pelvic LN in the radia-
tion field would increase the volume of normal tis-
sue being irradiated [2], the tolerance to the rectum 
was still maintained for patients with LN irradia-
tion. This may explain why no significant increase 
in the incidence of GI toxicities was observed. In 
addition, the lack of statistical significance could be 
due to the fact that the group with LN irradiation 
had only six patients. 
The potential relationship between patient age 
and toxicities could be due to the physiological 
changes linked with ageing and co-morbidities. 
However, this was not established in this study, 
which was in line with previous literature [34]. 
Furthermore, PCa radiotherapy treatments may 
still be improved to further spare normal tissues. 
The reason being that a significant number of pa-
tients experienced a higher incidence of GI toxici-
ties between the first and last week of radiotherapy 
treatment, since the baseline and follow-up toxicity 
scores were compared.
Limitations
Even though the population is small, the whole 
population was included in the study (exhaustive 
sampling). Despite the known limitations of ret-
rospective data collection, the EPIC score was sys-
tematically used as a data collection tool and very 
few patients were removed from the sample due to 
the lack of available data. Moreover, at a Maltese ra-
diotherapy centre, EPIC is filled in by the patient in 
the presence of a healthcare professional, in order 
to better explain the questions and avoid misunder-
standings. This allows the researchers to confidently 
argue that patient thickness does not predict well 
the incidence or the severity of GI side-effects.
Despite the effort to assess the influence of con-
founding factors, the subgroups for some of these 
factors were too small to establish valuable conclu-
sions. The influence of LN irradiation (and cor-
responding larger PTV) on toxicities could not 
be assessed since only six patients had undergone 
lymph node irradiation. The same applies to the 
rectum dose since all patients complied with the 
dose constraint assessed. A larger sample and more 
dose-volume parameters are recommended in fur-
ther studies.
The strength of the study is its novelty. Although 
the literature includes several studies which exam-
ined the association between toxicities and patients’ 
habitus, the conclusions are contradictory. Only 
one study made use of patient thickness as the 
measure for patient size, which is directly related 
to the attenuation of the beam [16]. Moreover, only 
one similar study utilised the EPIC tool to measure 
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toxicities, which is a widespread validated instru-
ment [18]. Therefore, this current study, combining 
both measurements, provides a novel approach to 
assessing GI toxicities and patient size. The inclu-
sion of different toxicities, surrogate measurements 
(such as thickness, weight, BMI), and cancer sites 
would enrich the study, yet this was not within the 
scope of this study, which is its limitation. A sug-
gested future study is to compare the relationship 
between patient size, using different surrogate 
measurements and assess if they differ in the pre-
diction of different acute and late toxicities (such as 
GI, urinary, skin, or fatigue).
conclusions
In this study, patient AP and lateral thickness 
were shown to have no significant effect on acute 
GI toxicities following PCa radiotherapy, when pa-
tients are treated with VMAT and image-guided 
radiotherapy. Therefore, irrespective of their thick-
ness, all patients should be offered the best care and 
follow-up.
The lack of relationship between patient size 
and toxicities confirms previously published lit-
erature [9, 13, 15] and contradicts other studies [7, 
8, 10, 11, 14], showing that toxicities are difficult 
to predict and may be multifactorial. Since all pa-
tients in this study were treated using VMAT and 
image-guided CBCT, and knowing the advantages 
of these techniques in terms of conformity, accu-
racy and decrease in OAR dose, this may explain 
the lack of difference in GI toxicities for different 
patient thickness. In addition, since the previous 
publications used a variety of techniques, this may 
also influence the results obtained.
However, radiation toxicities remain prevalent, 
showing that there is still room for improvement of 
radiotherapy treatments. Lastly, further research is 
necessary which focuses on different cancers, tox-
icities, methods of measuring patient size or toxic-
ity grade, and radiotherapy techniques to further 
elucidate the complex relationship between patient 
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